Review: Treatment of Patients with BRAF V600K-Mutant Melanoma Remains Under-Studied

Source: AJMC, March 2022

Existing research appears to suggest these patients can be treated similarly to patients with other genetic subtypes of cutaneous melanomas.

A new review article offers insights into patients with cutaneous melanomas with BRAF V600K mutations, a subgroup of patients in whom little specific study has occurred.

Writing in the Journal of Clinical Medicine, corresponding author Simone Ribero, MD, PhD, and colleagues said about half of patients with melanomas have a BRAF mutation, and the most common type is V600E. About 1 in 10 patients with a BRAF mutation have a V600K mutation, but no studies have been conducted with the specific aim of identifying the optimal therapy for this patient group, the investigators explained.